Showing 15 posts of 697 posts found.


Roche’s Phesgo combo secures US approval for metastatic HER2-positive breast cancer

June 30, 2020
Manufacturing and Production, Sales and Marketing FDA, Phesgo, Roche, US, breast cancer

The FDA has awarded marketing authorisation in the US to Roche’s Phesgo, a combination of subcutaneously injected Herceptin (trastuzumab) with …

Roche’s rheumatoid arthritis drug Actemra shows no benefit in COVID-19 pneumonia

June 18, 2020
Research and Development Actemra, COVID-19, Roche, coronavirus

Hope is waning around the efficacy of Roche’s Actemra (tocilizumab) following the release of results from an Italian study focusing …

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer

May 27, 2020
Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq

NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …


Genentech’s retiring R&D head to be replaced by MIT executive

May 15, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Roche, appointment

Michael Varney, industry veteran and Head of Research & Development at Genentech, has announced he is to leave the role …

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020
Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …


Roche signs multi-billion dollar RNA-targeted drug discovery deal with Arrakis Therapeutics

April 9, 2020
Research and Development, Sales and Marketing Arrakis, Roche, partnership, pharma

Roche has signed a new partnership with Arrakis Therapeutics in a bid to drive discovery of RNA-targeted small molecule (rSM) …

Roche shows improved survival rates in new treatment for untreated acute myeloid leukaemia

March 24, 2020
Manufacturing and Production Cancer, Roche, acute myeloid leukamia

Roche has announced that its clinical trials for Venclexta/Venclyzto combination with azacitidine have met its primary endpoints of overall survival …

FDA gives emergency authorisation to first coronavirus tests

March 17, 2020
Manufacturing and Production, Sales and Marketing FDA, Roche, US, coronavirus

The coronavirus crisis in the US has thus far been characterised by a lack of testing within its population. This …

Venclyxto combo scores European approval for previously untreated chronic lymphocytic leukaemia

March 13, 2020
Medical Communications, Sales and Marketing AbbVie, European Commission, Roche, Venclyxto, pharma

The European Commission has moved to authorise AbbVie and Roche’s B-cell lymphoma-2 (BCL-2) inhibitor Venclyxto (venetoclax) when used in combination …

China approves Roche’s Actemra to fight severe complications stemming from coronavirus

March 5, 2020
Sales and Marketing Actemra, China, Roche, coronavirus, pharma

China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …


NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma

February 26, 2020
Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche

It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …


Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials

February 10, 2020
Sales and Marketing Alzheimer's, Roche, roche Alzheimer

Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form …

Latest content